Thomas P. Mathers

Chief Executive Officer

Thomas P. Mathers

Tom joined CoLucid as Chief Executive Officer in 2011. He has more than nineteen years of executive management experience in the life sciences and medical device industry. Mr. Mathers also serves on the Board of Directors for the Biotechnology Industry Organization (BIO), and as chairman of Déclion Pharmaceuticals, a company which he co-founded.

Prior to CoLucid, Tom served as president and CEO of Peptimmune, Inc.; president and CEO of Cell Based Delivery; vice president and general manager of Cardion AG; vice president of Strategic Development at Genzyme; and management positions at Snowden-Pencer and Pfizer, Inc.

Tom holds several patents and patents pending and earned his BS in Engineering from the United States Military Academy at West Point, where he was a Dean's List student and three-year starter on the football team as a defensive end. From 1988 to 1991 he served as captain in the United States Army and was awarded several medals for his services as an AH-64 Apache helicopter pilot in the Gulf War in the XVIII Airborne Corps.

Education
United States Military Academy at West Point
(BS in Engineering)

Back to List

About Colucid

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures.

Learn More About CoLucid

Lasmiditan

image of lasmiditan structure

Lasmiditan is a member of a novel chemical class called "ditans." Lasmiditan penetrates the central nervous system (CNS) and selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway.

Learn More About Lasmiditan